KTC1101
KTC1101 is an orally active pan-PI3K inhibitor. KTC1101 can inhibit the PI3K signaling pathway, reduce downstream AKT and mTOR phosphorylation, and reduces the expression of Ki67. The anti-tumor effect of KTC1101 has a dual mechanism of action: directly inhibiting tumor cell growth and dynamically enhancing immune response[1].
Product Specifications
CAS Number
2764833-47-6
UNSPSC
12352005
Target
Akt; mTOR; PI3K
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ktc1101.html
Purity
98.09
Solubility
DMSO : 33.33 mg/mL (ultrasonic)
Smiles
FC(F)C1=NC2=C(OC)C=C(N)C=C2N1C3=NC(N4CCOCCC4)=NC(N5CCOCC5)=N3
Molecular Formula
C21H26F2N8O3
Molecular Weight
476.48
References & Citations
[1]Peng X, et al. A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation. Mol Cancer. 2024 Mar 14;23 (1) :54.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PI3K; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
EM1705 96 Tests
Mouse CAMP (Cathelicidin Antimicrobial Peptide) ELISA Kit
Sign In for Pricing
View Details 
